Chris Stevo | Senior Vice President and Chief Investor Relations Officer |
Albert Bourla | Chairman and Chief Executive Officer |
Dave Denton | Chief Financial Officer |
Mikael Dolsten | President-Worldwide Research and Development and Medical |
Angela Hwang | Group President, Pfizer Biopharmaceuticals Group |
Aamir Malik | Chief Business and Innovation Officer |
William Pao | Chief Development Officer |
Carter Gould | Barclays |
Robyn Karnauskas | Truist Securities |
Terence Flynn | Morgan Stanley |
Umer Raffat | Evercore ISI |
Mohit Bansal | Wells Fargo |
Evan Seigerman | BMO Capital Markets |
Louise Chen | Cantor Fitzgerald |
David Risinger | SVB Securities |
Tim Anderson | Wolfe Research |
Geoff Meacham | Bank of America |
Chris Schott | JPMorgan |
Chris Shibutani | Goldman Sachs |
Andrew Baum | Citi |
Steve Scala | Cowen |
Elliott Bosco | UBS |
Good day everyone and welcome to Pfizer's Second Quarter 2022 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chris Stevo, Senior Vice President and Chief Investor Relations Officer. Please go ahead, sir.